Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice
暂无分享,去创建一个
Huub Schellekens | Wim Jiskoot | W. Jiskoot | H. Schellekens | Francesca Gilli | Vera Brinks | F. Gilli | Melody Sauerborn | Miranda M. C. van Beers | V. Brinks | M. V. van Beers | M. Sauerborn
[1] S Porter,et al. Human immune response to recombinant human proteins. , 2001, Journal of pharmaceutical sciences.
[2] P. Gallo,et al. Interferon-beta (IFN-β) antibodies in interferon-β1a-and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo , 2001 .
[3] A. Bertolotto,et al. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments , 2005, Neurological Sciences.
[4] S. Kimura,et al. Stability of human interferon-beta 1: oligomeric human interferon-beta 1 is inactive but is reactivated by monomerization. , 1989, Biochimica et biophysica acta.
[5] J. Ralston,et al. Solution Behavior of IFN-β-1a: An Empirical Phase Diagram Based Approach , 2005 .
[6] John M. Walker,et al. The Protein Protocols Handbook , 2009, Springer Protocols Handbooks.
[7] J. Peter-Katalinic,et al. Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. , 1987, The Journal of biological chemistry.
[8] W. Jiskoot,et al. Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta , 2005, Pharmaceutical Research.
[9] Y. J. Wang,et al. Formulation, Characterization, and Stability of Protein Drugs: Case Histories , 2002, Pharmaceutical Biotechnology.
[10] A. Whitty,et al. The structure of human interferon-β: implications for activity , 1998, Cellular and Molecular Life Sciences CMLS.
[11] S. Kimura,et al. Stability of human interferon-ß1: oligomeric human interferon-ß1 is inactive but is reactivated by monomerization , 1989 .
[12] C. Wijbrandts,et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study , 2009 .
[13] A. Whitty,et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). , 1998, Pharmaceutical research.
[14] A. Hawe,et al. Stabilization of a hydrophobic recombinant cytokine by human serum albumin. , 2007, Journal of pharmaceutical sciences.
[15] Alastair Aitken,et al. Protein Determination by UV Absorption , 1996 .
[16] David W. Russell,et al. SDS-Polyacrylamide Gel Electrophoresis of Proteins. , 2006, CSH protocols.
[17] S Goelz,et al. The crystal structure of human interferon beta at 2.2-A resolution. , 1997 .
[18] J. Ralston,et al. Solution behavior of IFN-beta-1a: an empirical phase diagram based approach. , 2005, Journal of pharmaceutical sciences.
[19] Jochem Alsenz,et al. Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.
[20] G. Antonelli,et al. Reflections on the immunogenicity of therapeutic proteins. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[21] H. Eisenberg,et al. Light scattering , 1976, Nature.
[22] R. Herndon,et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis , 2005, Multiple sclerosis.
[23] W. Jiskoot,et al. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. , 2010, Journal of immunological methods.
[24] Paolo Gallo,et al. Immunogenicity of interferon beta: differences among products , 2004, Journal of Neurology.
[25] D. Roth,et al. Cell Cooperation in the Antibody Response , 2006 .
[26] M. Barkley,et al. Toward understanding tryptophan fluorescence in proteins. , 1998, Biochemistry.
[27] B. Smith,et al. SDS Polyacrylamide Gel Electrophoresis of Proteins. , 1984 .
[28] P. Sørensen,et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy , 2005, Neurology.
[29] P. Soelberg Sørensen. Review: Neutralizing antibodies against interferon-beta , 2008 .
[30] P. Sørensen. Neutralizing antibodies against interferon-Beta. , 2008, Therapeutic advances in neurological disorders.
[31] Patrick Mayeux,et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.
[32] Luyuan Zhang,et al. Ultrafast quenching of tryptophan fluorescence in proteins: Interresidue and intrahelical electron transfer , 2008 .
[33] J. Philo,et al. A critical review of methods for size characterization of non-particulate protein aggregates. , 2009, Current pharmaceutical biotechnology.
[34] A. Whitty,et al. Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity. , 2000, Biochemistry.
[35] Huub Schellekens,et al. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. , 2010, Trends in pharmacological sciences.
[36] M. Hora,et al. Interferon-β-1b (Betaseron ® ): A Model for Hydrophobic Therapeutic Proteins , 2002 .
[37] D. Weilguny,et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model , 1994, Diabetologia.
[38] A. Rosenberg,et al. Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.
[39] P. V. von Hippel,et al. Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.
[40] Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. , 2008, Journal of immunological methods.
[41] A. Hawe,et al. Development of HSA-free formulations for a hydrophobic cytokine with improved stability. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[42] Huub Schellekens,et al. Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2b , 2005, Pharmaceutical Research.
[43] P. Gallo,et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. , 2001, European cytokine network.
[44] Daan J.A. Crommelin,et al. Methods for structural analysis of protein pharmaceuticals , 2005 .
[45] J. Faro,et al. Immune responses to polysaccharides: lessons from humans and mice. , 2008, Vaccine.
[46] D. Paty,et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b , 1999, Neurology.
[47] Huub Schellekens,et al. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of Pharmacy and Science.
[48] P. Sørensen,et al. Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies? , 2008, Multiple sclerosis.
[49] T. H. Nguyen,et al. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. , 1995, Biochemistry.
[50] D. Volkin,et al. Ultraviolet absorption spectroscopy. , 1995, Methods in molecular biology.
[51] B. Dijkmans,et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study , 2009, Annals of the rheumatic diseases.
[52] Adrian Whitty,et al. Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β) , 1998, Pharmaceutical Research.
[53] A. Millonig,et al. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study , 2009, Multiple sclerosis.
[54] Amber Haynes Fradkin,et al. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. , 2009, Journal of pharmaceutical sciences.
[55] Huub Schellekens,et al. Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.
[56] V. Tomassini,et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years , 2003, Journal of the Neurological Sciences.